直接皮肤饲血与膜饲血评估高剂量伊维菌素杀蚊效力的比较(IVERMAL试验)
该研究嵌套于肯尼亚141例无并发症疟疾成人的随机双盲安慰剂对照试验,比较3天伊维菌素300或600 mcg/kg/day联合双氢青蒿素哌喹的杀蚊效果。
要点
- 治疗后第7天直接皮肤饲血与膜饲血的蚊虫14天累计死亡率相似。
- 膜饲血法更患者友好且伦理可接受,可可靠评估伊维菌素杀蚊效力。
- 结果在不同性别、BMI及伊维菌素毛细血管浓度范围内一致。
核心结论
- 直接皮肤饲血与膜饲血在第7天评估伊维菌素杀蚊效力结果相似,膜饲血可准确反映自然叮咬效果。
研究设计与样本
- 嵌套于随机双盲安慰剂对照试验的蚊虫饲血研究,141例肯尼亚无并发症疟疾成人中69例参与两种饲血。
主要发现
- 两个伊维菌素组合并后,直接皮肤饲血观察蚊虫2941只,膜饲血观察7380只。
- 结果按性别、BMI及伊维菌素毛细血管浓度范围(0.72-73.9 ng/mL)一致。
关键数值与推荐
- 伊维菌素用法为3天300或600 mcg/kg/day,均联合3天双氢青蒿素哌喹。
- 治疗后第7天进行直接皮肤和膜饲血试验,使用实验室饲养的冈比亚按蚊。
临床怎么用
- 膜饲血法患者友好且伦理可接受,可可靠用于评估伊维菌素杀蚊效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ivermectin is being considered for mass drug administration for malaria, due to its ability to kill mosquitoes feeding on recently treated individuals. In a recent trial, 3-day courses of 300 and 600 mcg/kg/day were shown to kill Anopheles mosquitoes for at least 28 days post-treatment when fed patients' venous blood using membrane feeding assays. Direct skin feeding on humans may lead to higher mosquito mortality, as ivermectin capillary concentrations are higher. We compared mosquito mortality following direct skin and membrane feeding. METHODS: We conducted a mosquito feeding study, nested within a randomized, double-blind, placebo-controlled trial of 141 adults with uncomplicated malaria in Kenya, comparing 3 days of ivermectin 300 mcg/kg/day, ivermectin 600 mcg/kg/day, or placebo, all co-administered with 3 days of dihydroartemisinin-piperaquine. On post-treatment day 7, direct skin and membrane feeding assays were conducted using laboratory-reared Anopheles gambiae sensu stricto. Mosquito survival was assessed daily for 28 days post-feeding. RESULTS: Between July 20, 2015, and May 7, 2016, 69 of 141 patients participated in both direct skin and membrane feeding (placebo, n = 23; 300 mcg/kg/day, n = 24; 600 mcg/kg/day, n = 22). The 14-day post-feeding mortality for mosquitoes fed 7 days post-treatment on blood from pooled patients in both ivermectin arms was similar with direct skin feeding (mosquitoes observed, n = 2941) versus membrane feeding (mosquitoes observed, n = 7380): cumulative mortality (risk ratio 0.99, 95% confidence interval [CI] 0.95-1.03, P = .69) and survival time (hazard ratio 0.96, 95% CI 0.91-1.02, P = .19). Results were consistent by sex, by body mass index, and across the range of ivermectin capillary concentrations studied (0.72-73.9 ng/mL). CONCLUSIONS: Direct skin feeding and membrane feeding on day 7 resulted in similar mosquitocidal effects of ivermectin across a wide range of drug concentrations, suggesting that the mosquitocidal effects seen with membrane feeding accurately reflect those of natural biting. Membrane feeding, which is more patient friendly and ethically acceptable, can likely reliably be used to assess ivermectin's mosquitocidal efficacy. CLINICAL TRIALS REGISTRATION: NCT02511353.
引用
- Smit MR, Ochomo EO, Aljayyoussi G, et al. Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial). Clin Infect Dis. 2019. PMID: 30590537. doi:10.1093/cid/ciy1063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。